Launch of VivaCyte® at Advanced Therapies Week 2024

Events

Launch of VivaCyte^® at Advanced Therapies Week 2024

Showcasing the VivaCyte® to the global cell therapy community

Advanced Therapies Week is the annual conference where new technologies and techniques are showcased that have the potential to revolutionize ways to develop, manufacture and administer these game-changing treatments.

Held in Miami in January 2024, ATW is the annual event where the global cell and gene therapy community come together. This year there was an anticipation of the impact advances in automation and AI will bring, and how wider adoption of these will positively impact the cell and gene therapy field.

To meet this expectation, VivaCyte was officially launched at ATW, showcasing how Cellply brought together innovative engineering, proprietary automated microfluidics and AI-powered image analysis to revolutionize cell therapy characterization, at single-cell resolution.

Throughout the conference a masterclass series entitled ‘Charting New frontiers in cell therapy with innovative single-cell characterization’ was hosted on our booth.

Featuring industry KoLs, Evren Alici, Head of Cell and Gene Therapy Group, Department of Medicine at Karolinska Institutet, and Richard Harbottle, Head of DNA Vector Research at German Cancer Research Centre (DKFZ), who discussed how VivaCyte is accelerating their work in translational studies of NK cell-based therapies and enabling quantification of a novel TCR-T cell manufacturing approach to enhance potency and reduce exhaustion, respectively.

On a practical note, the high level of automation in VivaCyte was highlighted as a game-changer, significantly increasing experimental throughput while freeing up their scientists’ time.

They were partnered with our Chief Strategy Officer, Massimo Bocchi, and Field Application Specialist, Francesco Imperatore, who presented real-world data linking in-vitro analysis of function and phenotype highlighting how single-cell multiparametric analysis enhances understanding of immunotherapy mode of action. And how subsequent cytotoxicity analysis reveals immune cell functional heterogeneity, providing actionable data for discovery and development.

The novel concept of a Unified Potency Score (UPS) was introduced to the ATW audience during these presentations. As the weighted average number of target cells killed by a single effector cell, it enables direct comparison of potency between patient/donor samples and between batches.

Evren Alici

Head of Cell and Gene Therapy Group, Department of Medicine, Karolinska Institutet

Richard Harbottle

Head of DNA Vector Research, DKFZ

Francesco Imperatore

Field Application Scientist at Cellply

Massimo Bocchi

Chief Strategy Officer and Founder at Cellply

Visitors at the booth

Cellply team

Vsitors at the booth

Cellply team

Scientific Poster Session

Joint poster with DKFZ accepted for presentation

Unified Potency Score

The novel concept of a Unified Potency Score (UPS) was introduced to the ATW audience during Masterclass series and also featured in the scientific poster co-authored with Richard Harbottle’s team at the DNA Vector Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Richard Harbottle presented the poster which highlighted how a UPS enables comparison of potency boosting cell engineering approaches and facilitates comparison of donors and product candidates.

One clear message came out of the masterclass and poster presentations: with the comprehensive characterization that VivaCyte provides, potential therapies featuring higher serial killing and better killing kinetics can now be rapidly identified and will enable the use of more potent cell therapy products requiring fewer immune cells to generate a patient response.
Richard and Massimo presented the poster which highlighted how a UPS enables comparison of potency boosting cell engineering approaches and facilitates comparison of donors and product candidates.

“The launch of VivaCyte here in Miami is the result of years of research by our entire team, whom I want to thank. The system brings together an unrivalled combination of comprehensive automation with the depth of analysis required to provide the insights the industry needs.”

Massimo Bocchi

Chief Strategy Officer, Cellply

An interview published on the official Phacilitate channel

Georgi Makin of Phacilitate interviewed Emiliano Spagnolo, CEO, and Massimo Bocchi, co-founder and Chief Strategy Officer at the meeting.

Click here to see the interview on the official Phacilitate channel. We hope that everyone enjoyed ATW 2024.

ATW24 - Video News Cellply V3 from Phacilitate on Vimeo.

Watch the video

News

Cellply wins an H2020 SME Instrument Phase 1 grant

20 October 2016

Keep in touch

Need some infos?

Drop us a line or give us a ring. We love to hear from you and are happy to answer any questions.

Launch of VivaCyte<sup>®</sup> at Advanced Therapies Week 2024